Apollon Formularies (AQSE:APOL) Total Payout Yield % : -222.62 (As of Jun. 01, 2024)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Apollon Formularies's current Total Payout Yield % is -222.62%.

Apollon Formularies Total Payout Yield % Historical Data

The historical data trend for Apollon Formularies's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Total Payout Yield % Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Total Payout Yield %

Get a 7-Day Free Trial

-2,092.49

-63.52

-12.61

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Total Payout Yield %	Get a 7-Day Free Trial											-	-444.17	-	-	-

Competitive Comparison of Apollon Formularies's Total Payout Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollon Formularies's Total Payout Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Total Payout Yield % falls into.

Apollon Formularies Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Apollon Formularies's Total Payout Yield % for the fiscal year that ended in Dec. 2021 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	2.5	+	0)	/	19.8319905
	=	-12.61%

Apollon Formularies's annualized Total Payout Yield % for the quarter that ended in Jun. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0	+	0)	*	2	/	1.34958425
	=	0.00%

Apollon Formularies Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Apollon Formularies Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.